Market
Scenario
Acute
intermittent porphyria (AIP) is a genetic metabolic disorder. It affects the
production of heme, the oxygen-binding prosthetic group of hemoglobin.
Generally, it is characterized by a deficiency of the enzyme porphobilinogen
deaminase.
The major
causes of acute intermittent porphyria are abnormal urinary color, anorexia,
insomnia, myalgia, and urinary retention. In some cases, AIP develops liver
cancer (hepatocellular carcinoma), and some develop kidney failure. Other
symptoms include gastrointestinal issues, urinary tract issues, neurological
issues, psychiatric issues.
The acute
intermittent porphyria market growth is majorly attributed to the increasing
prevalence of the metabolic disorders, gastrointestinal issues, urinary tract
issues, and healthcare insurance coverage. Moreover, increasing geriatric
population will drive the market growth.
According
to the Economic and Social Commission for Asia and the Pacific (ESCAP), in
2016, approximately 12.4% of the population in the region was over 60 years.
According to Asian Development Bank, it was estimated that by 2050, 15% of
total Malaysian population will be over 65 year old and in China, the elderly
population will reach over 300 million by 2050. Thus, the increasing geriatric
population in Asia is likely to help the growth of the market over the forecast
period.
According
to the WHO estimates, neurological disorders are responsible for 4.5%-11% of
all illnesses including low or high income economies. This is far higher as
compared to the number of respiratory ailments, gastrointestinal disorders, or
cancers, and the burden is expected to increase further over the coming years.
According
to the American Liver Foundation, there is an increasing the prevalence of
liver disease in the U.S. from then last few years. It further stated that at
least 30 million people have some form of liver disease.
However,
availability of expensive treatment and poor reimbursement policies in the
developing regions of the world are some of the factors, which may hamper the
market growth during the forecast period.
The
global acute intermittent porphyria market is expected to grow at a CAGR of 5.6
% during the forecast period 2017-2023.
Intended
Audience
- Pharmaceutical
Companies
- Research
and Development (R&D) Companies
- Government
Research Institute
- Academic
Institutes and Universities
- Medical
Research Laboratories
- Market
Research and Consulting Service Providers
- Potential
Investors
Segmentations
The
global acute intermittent porphyria market is segmented on the basis by
diagnosis, by treatment, and by end user.
On the
basis of diagnosis, it is segmented into blood test, urine test, serum test,
DNA test, and others.
On the
basis of treatment, it is segmented into gonadotropin-releasing hormone
analogues, prophylactic hematin infusions, and others.
On the
basis of end user, it is segmented into hospitals & clinics, research
centers, and others.
Regional
Analysis
The
Americas dominate the global acute
intermittent porphyria market owing to well-developed technology, increasing
patient with genetic metabolic disorders, high healthcare spending, and
increasing government support for research & development. Furthermore,
increased R&D activities and the concentration of major companies have
fuelled the growth of the market in this region.
Europe
holds the second position in the global acute intermittent porphyria market
owing to the government support for research & development and availability
of funds for research. This is expected to continue to drive the European
market over the forecasted period. For instance, countries like Germany and
France are increasing investment in the healthcare domain.
Asia
Pacific is the fastest growing acute intermittent porphyria market owing to the
presence of rapidly developing healthcare technology, huge patient population,
and high healthcare expenditure. Moreover, increasing demand for new treatment
methods in countries like India and South Korea is likely to emerge as the
fastest growing market across the globe. Furthermore, increasing demand for quality
devices in the healthcare projected to lead to the use of advanced equipment,
which, in turn, will increase the market growth of the acute intermittent
porphyria in the region.
On the
other hand, in the Middle East and Africa, blood disorders have become a huge
problem due to limited screening, ignorance of diseases, and poor access to
treatment.
Key
Players
Some of
key the players in the market are Dahaner (U.S.), F. Hoffmann-La Roche Ltd
(Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.),
ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), ACON Laboratories, Inc.
(U.S.).
Detailed Table
of Contents:
1. Report Prologue
2. Market Introduction
2.1
Definition
2.2
Scope Of The Study
2.2.1
Research Objective
2.2.2
Assumptions
2.2.3
Limitations
3. Research Methodology
3.1
Introduction
3.2
Primary Research
3.3
Secondary Research
3.4
Market Size Estimation
4. Market Dynamics
4.1
Drivers
4.2
Restrains
4.3
Opportunities
4.4
Challenges
4.5
Macroeconomic Indicators
4.6
Technology Trends & Assessment
...Continued
About US:
Market Research Future (MRFR), enable
customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment